Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Pediatric genetic epilepsies like CDKL5 Deficiency Disorder (CDD) cause severe, early-onset seizures, often unresponsive to conventional treatments.
• Limited research exists on cannabinoid therapies for CDD, with current evidence often anecdotal and lacking compositional data.
• Relaxed cannabis legislation has spurred interest in phytocannabinoids like cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) for epilepsy.

Purpose of the Study:

• To review the therapeutic potential of CBD, THC, and other cannabinoids for CDKL5 Deficiency Disorder.
• To explore the mechanisms of action of cannabinoids in disrupted CDD pathways.
• To strengthen the case for further research into cannabinoids as anti-epileptic drugs for CDD.

Main Methods:

• Review of existing clinical trials and preclinical models investigating cannabinoid efficacy in epilepsy.
• Exploration of patient-derived iPSC neurons and brain organoids for precise cannabinoid dosing and pharmacodynamic studies.
• Analysis of anecdotal reports and artisanal cannabinoid products.

Main Results:

• CBD has demonstrated antiseizure properties, particularly in drug-resistant genetic epilepsies like LGS, DS, and TSC.
• Preclinical models and iPSC-derived neurons allow for controlled investigation of cannabinoid effects in CDD.
• Limited specific data exists for CDD, highlighting the need for rigorous scientific study.

Conclusions:

• Cannabinoids, including CBD and THC, represent a potential therapeutic avenue for CDD.
• Further research utilizing advanced model systems is crucial to elucidate mechanisms and confirm efficacy.
• Strengthening evidence for cannabinoid-based treatments could significantly improve quality of life for CDD patients and families.